Subject: Fw: new article - "Hepatitis B Core Antibody: Role in Clinical Practice in 2020"
From: Robert Gish <[email-masked]>
To: Undisclosed recipients:Undisclosed
Date: Wed, 30 Sep 2020 01:32:27 +0000

The article referenced below has been converted to Open Access and is attached for your use, with link below for additional sharing.

https://link.springer.com/article/10.1007/s11901-020-00522-0

Thank you,

Robert G. Gish MD

+1 858 229 9865

From: Sarah Livingston on behalf of Robert Gish

Sent: Monday, July 13, 2020 8:51 AM

Subject: new article - "Hepatitis B Core Antibody: Role in Clinical Practice in 2020"

Thank you all for input from colleagues in the hepatology community to help update all providers on the facts about anti-HBc.

You can read the newly published article here:

https://rdcu.be/b5zpZ

2 key take-away points

False + rate for current anti-HBc testing is 2/1,000

Anti-HBc + (total) test = cccDNA

Risk for reactivation

No need for HBV vaccine

Consider evaluation for OBI in clinical setting of anti-HBc alone

There is no current peer reviewed data that patients clear cccDNA after acute HBV and total anti-HBc+ tracks the presence of cccDNA

Cautious use of anti-HBc IgM use in clinical practice to diagnose and manage “acute HBV”

Thank you,

Robert G. Gish MD

+1 858 229 9865